

Principle, technology and cutting-edge applications of Spectral CT imaging

Speaker: Salim A. Si-Mohamed (MD, PhD), Associate Professor
salim.si-mohamed@chu-lyon.fr, <https://www.spectralphotoncountingct.com/>

Affiliations

^a – Hôpital cardiothoracique et vasculaire, Louis Pradel, Lyon


^b – University of Lyon : LabCREATIS, Team MYRIAD, CNRS – INSERM – Université Lyon 1 – INSA



6 Clinical dual-layer dual-energy CT platform (University hospitals, Hospices Civils de Lyon)



Clinical and pre-clinical Spectral Photon-Counting CT platform (CERMEP) (University of Lyon)



Who wants to improve patient survival ?

Teaching points


- Explain basic principles of Spectral CT imaging
- Differentiate the technology between dual and multi-energy CT
- Understand the clinical implications
- Be able to identify and discover new applications

Introduction




1895

Introduction



Introduction



« A must read » technical review on Spectral CT technology
Greffier J, Villani N, Defez D, Dabli D, Si-Mohamed S. DIII. 2023
French national working group SFR, G4, SFPM, CERF

I. Principles

Principle

$$\mu(E) = \mu_P(E) + \mu_C(E) = \alpha_P f_P(E) + \alpha_C f_C(E)$$

$(\alpha_P, \alpha_C, \alpha_{K-edge})$: tissue-type specific

$$\alpha_P = D Z_{eff}^3$$

$$\alpha_C = D k$$

D : tissue density, et Z_{eff} : atomic number

(f_P, f_C) : depend only on the energy

$$f_P = 1/E^3$$

$f_C = 1/E^{0.3}$ = Klein and nishina fonction

E : photon energy

Principle

$$\mu(E) = \mu_P(E) + \mu_C(E) = \alpha_P f_P(E) + \alpha_C f_C(E)$$

$$\left\{ \begin{array}{l} \mu(E_L) = \alpha_P f_P(E_L) + \alpha_C f_C(E_L) \\ \mu(E_H) = \alpha_P f_P(E_H) + \alpha_C f_C(E_H) \end{array} \right.$$

Pros

- Generate tissue attenuation at different energies
- Generate specific images of tissue and contrast agent
- Generate specific image of chemical and physical composition of tissue

Material decomposition images

- Material decomposition in 2 basis based on their specific attenuation

$$\left\{ \begin{array}{l} \mu(E_B) = \alpha_P f_P(E_B) + \alpha_C f_C(E_B) \\ \mu(E_H) = \alpha_P f_P(E_H) + \alpha_C f_C(E_H) \end{array} \right.$$




$$\left\{ \begin{array}{l} \mu(E_B) = [C^\circ]_{iode} \mu_{iode}(E_B) + [C^\circ]_{eau} \mu_{eau}(E_B) \\ \mu(E_H) = [C^\circ]_{iode} \mu_{iode}(E_H) + [C^\circ]_{eau} \mu_{eau}(E_H) \end{array} \right.$$

- Measurement of tissue/agents concentrations based on specific attenuation

Material decomposition images

- Material decomposition in 2 basis based on their specific attenuation

Iodine-type image




Water-type image



Material decomposition images

Z effectif




Electronic density




- But it offers many different solutions to be explored & validated


Spectral CT imaging = Multiparametric imaging modality



Mono E 40 – 200 keV




Two basis MD



Z-effectif




Electronic density




Color K-edge imaging

II. Technology


Technology



Energy integrating detectors (EIDs)



Technology



Energy integrating detectors (EIDs)

Advantages & Limitations of dual-energy CT technology

1. Perform a material decomposition of the Photoelectric and Compton effects

BUT

1. Perform a limited sampling of the transmitted spectrum in 2 energy windows
2. Limitations of EIDs:
 1. Limited spatial resolution
 2. Limited dose efficiency
 3. Absence of energy-resolving capabilities

Technology






Figure 6.14 Schematic diagram of a semiconductor direct-conversion detector.

Energy integrating detectors (EIDs)


Photon-counting detectors (PCDs)

Technology




Photon-counting detectors (PCDs)

Impact on spatial resolution



Technology



Technology






Figure 2. Example of a 500ns signal output of a PCD pixel.

Impact on the noise




Technology






Impact on detectability

EIDs

PCDs



Technology



Technology

2 basis model

$$\mu(E) = \mu_P(E) + \mu_C(E) = \alpha_P f_P(E) + \alpha_C f_C(E)$$

$$\left\{ \begin{array}{l} \mu(E_B) = \alpha_P f_P(E_B) + \alpha_C f_C(E_B) \\ \mu(E_H) = \alpha_P f_P(E_H) + \alpha_C f_C(E_H) \end{array} \right.$$

$(\alpha_P, \alpha_C, \alpha_{K-edge})$: tissu-)type specific

$$\alpha_P = d Z_{eff}^3$$

$$\alpha_C = d k$$

D : tissue density, et Z_{eff} : atomic number

(f_P, f_C) : energy dependant

$$f_P = 1/E^3$$

$f_C = 1/E^{0.3} = \textbf{Klein and Nishina}$ fonction

E : photon energy

3 basis model

$$\mu(E) = \mu_P(E) + \mu_C(E) + \mu_{K-edge}(E)$$

$$\mu(E_{bin\ 1}) = \alpha_P f_P(E_{bin\ 1}) + \alpha_C f_C(E_{bin\ 1}) +$$

$$[C^\circ]_{K-edge} \mu_{K-edge}(E_{bin\ 1})$$


$$\mu(E_{bin\ 2}) = \alpha_P f_P(E_{bin\ 2}) + \alpha_C f_C(E_{bin\ 2}) +$$

$$[C^\circ]_{K-edge} \mu_{K-edge}(E_{bin\ 2})$$

$$\mu(E_{bin\ X}) = \alpha_P f_P(E_{bin\ X}) + \alpha_C f_C(E_{bin\ X}) +$$



$$[C^\circ]_{K-edge} \mu_{K-edge}(E_{bin\ X})$$

Color K-edge imaging



- Absolute quantification of multi-contrast agent imaging

Color K-edge imaging



➤ Absolute quantification of multi-contrast agent imaging

Advantages & Limitations of multi-energy SPCCT technology

1. Improve the intrinsic spatial resolution
2. Reduce the electronic noise
3. Improve the contrast
4. Perform a more accurate sampling of the transmitted spectrum
5. Identify the photoelectric effect of a contrast agent around its K-edge energy
6. Provide unprecedented specific and quantitative imaging of a contrast agent



BUT

Emerging technology in need of development & validation

III. Current applications of Spectral CT imaging

Clinical applications in need of quantification


❖ Iodine and water images enables to quantify physiopathological process



Clinical applications in need of functional imaging


❖ Iodine images provides a functional imaging of diseases

Nuclear imaging (SPECT/CT)



Functional imaging

Iodine image



Functional imaging

Si-Mohamed et al. In vivo demonstration of pulmonary microvascular involvement in COVID-19 using dual-energy computed tomography. ERJ. 2020

Clinical applications in need of functional imaging

❖ Iodine images provides a functional imaging of diseases

- Sars-COV2
- First phase

Conventional image **PBV**

Iodine image



Morphology imaging


Functional imaging

Si-Mohamed et al. In vivo demonstration of pulmonary microvascular involvement in COVID-19 using dual-energy computed tomography. ERJ. 2020

Clinical applications in need of functional imaging

❖ Functional imaging provides a characterization of disease course


- Sars-COV2
- Disease course




Si-Mohamed et al. In vivo demonstration of pulmonary microvascular involvement in COVID-19 using dual-energy computed tomography. ERJ. 2020

Clinical applications in need with multimodality imaging

❖ Tissue characterization




Nuclear imaging



Si-Mohamed et al. JACC: CV imaging. 2021

Invasive right heart catheterization




Si-Mohamed et al. JCM. 2023

Scully P.R. et al. JACC: CV imaging. 2020


IV. Incremental applications of spectral photon-counting CT

Detection of elementary structures


Conventional CT
120 kVp/103 mAs
FBP/SW 0.800 mm




SPCCT
120 kVp/63 mAs
FBP/SW 0.250 mm




Detection of elementary structures




2010 mm²
Zoom 5x



Detection of elementary structures




366 mm²
Zoom 15x




Quantification of elementary lesions

HRCT



W, 39 yo
SSc

SPCCT




Clinical impact of Spectral CT imaging

1. Earlier detection of disease
2. More precise diagnosis
3. More reliable diagnosis
4. Substitutive of invasive imaging


BUT

1. Need to adapt the work flow
2. Need to retrain the semiology




V. Cutting edge applications

Color K-edge imaging



Color K-edge contrast agents

Diagnostic energy range




Iodine K-edge
33.3 keV




- Need to develop and validate dedicated K-edge contrast agents


Color K-edge coronary angiography



Acide gadotérique, 0.5 M (Dotarem)



Coronary spectral photon-counting K-edge imaging



Color K-edge aortic angiography

Conventional
images

K-edge
images

Hybrid Nano-GdF₃ Contrast Media





Figure 1. Transmission Electron Microscopy of GdF₃ nanoparticles (left); High resolution of the crystalline nanoparticles (middle) and powder X-Ray Diffraction pattern (right).



Color K-edge myocardial perfusion

Development of a 1.25 M (700 mg/ml) of gadoteridol



Giuseppe Digilio

Assistant Professor

Dipartimento di Scienze e Innovazione Tecnologica DISIT

Amedeo Avogadro University of Eastern Piedmont

[Academic profile](#)







Figure. Dynamic K-edge SPCCT angiography with a high concentrated gadolinated contrast agent (Bracco, Milan, Italy) allowing for the visualization of the lung and myocardium enhancement. The K-edge images allow a quantitative analysis for myocardial perfusion as shown on the graph with a peak value found to be around 2 mg/mL

Color K-edge atherosclerotic aortic angiography




Patent N ° 22306578.0

Color K-edge lung perfusion imaging



Conventional imaging


Functional Color K-edge imaging



Color K-edge lung perfusion imaging




Conventional imaging




Only relative attenuation of -466 HU

Functional Color K-edge imaging



Absolute C° of 2.6 mg/mL


Color bi-modal K-edge myocardial infarction imaging



Conventional CT

Color K-edge

Fusion




Color bi-modal K-edge myocardial infarction imaging




SPCCT

Cardiac MR

Staining TTC





Bi-Color functional K-edge imaging



➤ **Simultaneous imaging of 2 physiological processes**



Molecular functional color K-edge imaging



Dr Cormode's lab





Nanomedicine and Molecular Imaging Lab



Si-Mohamed et al. Nanoscale. 2017


Molecular functional bi-color K-edge imaging



Gold K-edge image



Iodine image



Dr Cormode's lab



Bi-color K-edge imaging for cell tracking

SPCCT monitors and quantifies therapeutic cells and their encapsulating scaffold in a model of brain damage



CREATIS

LAGEP



Gold nanoparticles


AuNPs

AuNP-labeled therapeutic cells

Intracerebral transplantation




Spectral photon-counting CT



Specific cell tracking with Gold K-edge image



Quantification





Theranostic imaging


Conventional imaging



Color K-edge imaging with a radioluminescent contrast agent




Luminescence induced by X-rays for dynamic phototherapy




Versatility of Spectral CT imaging


Spectral ultra-high resolution imaging with lower X-ray dose and higher contrast




Color functional imaging




Color molecular imaging





Luminescence Color imaging



Multicolor Cell tracking




Multi-color imaging



« The time has come to color lung diseases »



April 2024 for 5 years
Positions available !!
Post-doc, PhD, Eng, MSc



ERC starting grant : KOLOR SPCCT Imaging

However, patience is required

Table 6. Main characteristics of current spectral photon-counting CT systems suitable for clinical imaging. Note that 2 of them are designed with small bore gantry for head (Samsung Healthcare) and for extremities (MARS Bioimaging limited system) imaging and that 2 of them have been FDA-cleared (Siemens Healthineers and Samsung Healthcare).

Manufacturer	CT platforms	PCD materials	Geometry	Detector size at isocenter	Field-of-view	Energy thresholds	Current status
Canon Healthcare	Aquilion ONE VISION	CdZT	Mono-source	0.342 mm	50 cm	6 available	Clinical prototype system; Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability; Clinical trial pending
GE Healthcare	LightSpeed VCT CT Scanner	Silicon	Mono-source	0.250 mm	?? cm	8 available	CT performances evaluation on going; Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability
MARS Bioimaging Limited (MBI)		CdZT	Mono-source	0.110 mm	11 cm	5 in “charge summing mode”	Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability; Pre-clinical research; Clinical trial pending
Philips Healthcare	Philips iCT platform	CdZT	Mono-source	0.274 mm	50 cm	5 in standard mode; 5 in HR modes	CT performances evaluation on going; Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability; Clinical trial pending
Samsung Healthcare	OmniTom Portable PCD Head CT	CdT	Mono-source	0.12 mm (UHR); 0.4 mm (HR); 0.7 mm (standard)	25 cm	3 available	Clinical research on Human; FDA-cleared in march 2022; Clinical trial pending
Siemens Healthineers	NAEOTOM Alpha	CdT	Dual-source	0.300 mm (standard); 0.150 mm (HR)	50 cm; 36 cm used for cardiac scans; 36 cm for high helical pitch scans	4 in standard mode; 2 in HR mode	FDA-cleared in september 2021; Pre-clinical and Clinical research on HumanFDA-cleared in september 2021; Commercially available

Footnote. Parameters listed are based on the current status of the manufacturer's development and are expected to evolve in a near future. Cd: Cadmium, Z: zinc, T: telluride.

Conclusion

Spectral CT imaging promises to push back the limits of conventional imaging by :

- Providing **incremental improvement** of current applications
- Providing **paradigm shift** for current applications
- Offering new **high-resolution morpho-functional applications** at the forefront of biology, chemistry, medical imaging, bio-engineering

High potential for improving the current state-of-care

High potential for improving the patients's survival

Principle, technology and
cutting-edge applications of
Spectral CT imaging



Follow us

kolor spcct imaging

<https://www.spectralphotoncountingct.com/>

Speaker: Salim A. Si-Mohamed (MD, PhD), Associate Professor
salim.si-mohamed@chu-lyon.fr, <https://www.spectralphotoncountingct.com/>

Affiliations

^a – Hôpital cardiothoracique et vasculaire, Louis Pradel, Lyon

^b – University of Lyon : LabCREATIS, Team MYRIAD, CNRS – INSERM – Université Lyon 1 – INSA

